CD274 and non-small cell lung carcinoma: Atezolizumab, an anti-PD-L1 monoclonal antibody, was studied in patients with brain metastases and previously treated NSCLC patients in the OAK trial and demonstrated a benefit of atezolizumab compared with docetaxel in the overall population, regardless of history of asymptomatic, treated brain metastases.